

1

2 **Increased naïve CD4+ and B lymphocyte subsets associated with body**
3 **mass loss drive relative lymphocytosis in anorexia nervosa patients**

4

5 Ana Elegido, BSc¹; Montserrat Graell M.D. PhD^{2,3}; Patricia Andrés, BSc²; Alina
6 Gheorghe, BSc¹; Ascensión Marcos, PhD¹; Esther Nova, PhD¹.

7

8 ¹Immunonutrition Research Group, Department of Metabolism and Nutrition, Institute
9 of Food Science, Technology and Nutrition (ICTAN) – CSIC. C/José Antonio Novais
10 10. 28040. Madrid. Spain.

11

12 ²Eating Disorders Unit. Child and Adolescent Psychiatry and Psychology Department.
13 Children University Hospital Niño Jesús. Av Menéndez Pelayo, 65, 28009
14 Madrid.Spain.

15 ³CIBERSAM (Biomedical Research Networking Centre for Mental Health. Ministry of
16 Health. Spain).

17

18 Corresponding Author: Esther Nova (enova@ictan.csic.es). Institute of Food Science,
19 Technology and Nutrition. ICTAN-CSIC. C/José Antonio Nováis 10. 28040. Madrid.
20 Spain. Ph: +34 915492300. Fax: +34 915493627

21

22 This is the accepted version of the manuscript that is accessible online at the following
23 link: <https://doi.org/10.1016/j.nutres.2017.02.006>

24

25 **Abstract**

26

27 Anorexia nervosa (AN) is an atypical form of malnutrition with peculiar changes in the
28 immune system. We hypothesized that different lymphocyte subsets are differentially
29 affected by malnutrition in AN and thus, our aim was to investigate the influence of
30 body mass loss on the variability of lymphocyte subsets in AN patients. A group of 66
31 adolescent female patients, aged 12-17 years referred for their first episode of either AN
32 or Feeding or Eating Disorders Not Elsewhere Classified (FED-NEC) were studied
33 upon admission (46 AN-restricting subtype [ANR], 11 AN-binge/purging subtype
34 [ANP] and 9 FED-NEC). Ninety healthy adolescents served as controls. White blood
35 cells and lymphocyte subsets were analyzed via flow cytometry. Relationships with the
36 BMI z-score were assessed in lineal models adjusted by diagnostic subtype and age.
37 Leukocyte numbers were lower in AN patients than in controls, and relative
38 lymphocytosis was observed in ANR. Lower CD8+, NK and memory CD8+ counts
39 were found in eating disorder patients compared to controls. No differences were found
40 for CD4+ counts or naïve and memory CD4+ subsets between the groups. Negative
41 associations between lymphocyte percentage and the BMI z-score, as well as between
42 the B cell counts, naïve CD4+ percentage and counts and the BMI z-score were found.
43 In conclusion, increased naïve CD4+ and B lymphocyte subsets associated with body
44 mass loss drive the relative lymphocytosis observed in anorexia nervosa patients, which
45 reflects an adaptive mechanism to preserve the adaptive immune response.

46

47 **Keywords:** anorexia nervosa, body mass loss, lymphocyte subsets, relative
48 lymphocytosis, white blood cells.

49

50 **Abbreviations:**

51

52 AN; Anorexia nervosa

53 ANP; Anorexia nervosa binge/purging subtype

54 ANR; Anorexia nervosa restricting subtype

55 BMI; Body mass index

56 BN; Bulimia nervosa

57 CD3+; T Mature cells

58 CD4+; Helper T cells

59 CD8+; Cytotoxic T cells

60 CD19+; B cells

61 CD3+(CD16+56+); Natural killer cells

62 CD45RA+; Naïve cells

63 CD45RO+; Memory cells

64 DSM; Diagnostic and Statistical Manual of Mental Disorders

65 ED; Eating disorders

66 FED-NEC; Feeding or Eating Disorders Not Elsewhere Classified

67 NK; Natural killer cells

68 WBC; White blood cells

69

70 **1. INTRODUCTION**

71

72 Eating disorders (ED) are mental disorders characterized by abnormal cognitions,
73 attitudes and behaviors towards food and body weight and shape. This results in severe
74 physical and psychological complications. Studies on hematological and immune
75 variables have disclosed some features of an impaired immune system status, including
76 an increased frequency of leucopenia with relative lymphocytosis [1, 2], delayed
77 hypersensitivity skin test response [1, 3], and an impaired cytokine production in
78 response to a stimulus when compared with a control group [4]. Relative lymphocytosis
79 refers to an increased percentage in peripheral lymphocytes among the white blood cells
80 while absolute lymphocyte number is normal [5]. Regarding lymphocyte subsets in ED
81 patients, a rather scarce number of studies have been published [1, 6-12], and the
82 findings are not consistent. Some of these studies have important drawbacks derived
83 from the heterogeneity of the participating patients, including issues like age [7, 8],
84 duration of the disease [7], subtype of anorexia nervosa (AN) or ED categories [6, 7, 8,
85 9] and history of dieting [13].

86

87 According to the diagnostic criteria established in the DSM V [14], AN is a disorder
88 characterized by a persistent restriction of energy intake leading to significantly low
89 body weight, an intense fear of fatness, and a disturbed perception of body image; in
90 bulimia nervosa (BN) the distinguishing feature is binge eating, accompanied with
91 compensatory behaviors, and both syndromes differ in their effects on body weight and
92 nutritional status. Besides, vomiting episodes can be considered to be one of the most
93 common stress-inducing bulimic features that might have an influence on the immune
94 system [15]. Feeding or Eating Disorders Not Elsewhere Classified (FED-NEC)

95 includes patients that do not meet full criteria for a specific ED but still present some of
96 their clinical features, although less severe or frequent. In addition, BN has recently
97 been described as a continuum of the disease in former patients with AN [16], and for
98 this reason the mean age is superior compared to patients with AN. Within the AN
99 disorder two subtypes have been defined: the restricting type and the binge-purging
100 type, the last one presenting binge-eating and/or purging behavior (e.g. self-induced
101 vomiting, misuse of laxatives, diuretics or enemas).

102

103 In AN, immune disturbances are most likely the result of nutritional deprivation,
104 and in this sense, normalization with re-feeding and clinical recovery has been reported
105 [9, 13]. The extent of the immune and metabolic changes depends on the duration and
106 severity of the reduced food intake and the amount of weight lost [11, 12, 17]. As a
107 result, different white blood cell types might be differentially affected by the degree of
108 malnutrition. On the other hand recent research suggests that other factors different
109 from weight and linked with alterations in hormones and neuropeptides involved in
110 appetite and satiety control may play an important role in explaining some of the
111 immune system abnormalities [18]. Considering all of the above, we hypothesize that
112 different immune cells and specifically lymphocyte subsets are differentially affected by
113 the malnutrition severity. Thus, the aim of this study was to assess the influence of body
114 mass loss on the variability of lymphocyte subsets in ED patients .

115

116 **2. METHODS AND MATERIALS**

117

118 **2.1 Participants**

119

120 The sample size for this study was calculated taking lymphocyte percentage as the main
121 outcome, assuming a mean \pm standard deviation of 34.23 ± 8.96 (%) in healthy female
122 adolescents [1]. and considering a 12% mean change (4%) over the values in the
123 population as relevant. For an unbalanced allocation ratio between control and patients
124 groups (1.36), an estimated mean difference of 12% with equal variances, 80%
125 statistical power and an alpha error of 0.05, the minimum number of measures to
126 perform is 156, distributed 90 to 66 in control and patients groups, respectively.

127

128 Sixty six adolescent female patients diagnosed with eating disorders were
129 recruited upon admission at the Eating Disorders Unit at Niño Jesús Children University
130 Hospital (NJCUIH) in Madrid, Spain, to participate in a comprehensive study of clinical,
131 family and biological variables involved in prognosis of ED (ANABEL study). The
132 following inclusion criteria were taken into account: 1) female gender, 2) age range
133 between 12-17 years, 3) first episode of ED, 4) first admission for ED treatment [19, 20]
134 5) acceptance to participate in the study. One hundred and five patients were first
135 screened for inclusion in the study during the years of 2010 to 2012; twenty six were
136 excluded because they did not fulfill all inclusion criteria and thirteen patients rejected
137 to participate in the study. The patients were classified as: AN-restricting subtype
138 (N=46), AN-binge/purging subtype (N=11) or FED-NEC (N=9), according to the DSM
139 V criteria [14]. The patients were initially diagnosed according to DSM IV-TR criteria
140 [21] by clinical interview performed by clinical experts, but were later reclassified
141 according to the DSM-V [14, 22] in order to be in line with current operational criteria.
142 This fact allowed to reduce the number of patients with no otherwise specified category
143 [23] from 17 to 9 patients. The control group consisted of 90 healthy adolescents, free
144 of psychiatric or somatic disease as answered in auto-administered and parent's

145 questionnaires, with the same gender, age and socioeconomic status, who participated in
146 the AFINOS epidemiological study [24]. No patient included in the study had had any
147 vaccine administered within the six weeks prior to the day of blood sampling, nor had
148 they been hospitalized for infections or other illnesses. Most of the patients at study
149 enrollment had been recently admitted for in-hospital treatment (75.76 %), and a lower
150 number were admitted to follow home care hospitalization (21.20 %), and out-patient
151 treatment (3.03 %). Seventy one percent of in-patients were at or below 10th BMI for
152 age percentile [25]. Participants and parents gave their full and informed consent once
153 the purpose and nature of the study had been explained. The study was conducted
154 according to the guidelines of the Declaration of Helsinki, the rules of Good Clinical
155 Practice and the Spanish law 14/2007 on Biomedical Research. The study protocol was
156 approved by the Ethics Committee of the NJCUH.

157

158 **2.2 Anthropometric measurements**

159

160 All patients and controls underwent anthropometrical assessment by standard
161 procedures (without shoes and with underwear clothes) measured by a trained
162 investigator. Patients' measurements were performed on their first day of admission or
163 on the following day using a digital electronic weighing scale (Seca 780; 0.100 g
164 precision) with an incorporated telescopic measuring rod (Seca 220), and the
165 measurements were recorded to the nearest 0.5 cm.

166

167 From these data, body mass index (BMI) [weight (kg)/height² (m²)] and Z-score
168 of the BMI were calculated according to the Spanish growth reference charts [25].

169

170 2.3 Blood Analysis

171

172 Venous blood samples were obtained from patients and controls between 8-9 AM, after
173 overnight fasting, the next day after enrollment, and they were collected in EDTA-K3E
174 Vacutainer (BD Biosciences) tubes. WBC counts and differentials (percentages and
175 absolute number of white cell types) were determined in patients and control subjects
176 with an automated blood cell counter (ADVIA 120) and an automatic counter (HI
177 Technicon (Bayer)), respectively. Blood samples from patients were diluted 1:1 with
178 Cytochex™ Reagent (Streck Laboratories, Omaha, NE, USA), a preservative that was
179 used to expand the number of suitable days for blood processing. Subsequently,
180 immune phenotyping analysis of the samples was performed within 7 days from
181 collection. Blood aliquots were incubated for 30 minutes at room temperature in the
182 dark with fluorochrome-conjugated monoclonal antibodies (BD Biosciences, San José,
183 CA, USA) to differentially label those cells positive for the following surface markers:
184 CD45 (pan-leukocyte marker), CD3 (T mature cells), CD4 (helper T cells), CD8
185 (cytotoxic T cells), CD19 (B cells), CD16+56 (natural killer cells), CD45RO (memory
186 cells) and CD45RA (naïve cells) [26]. A quadruple immunostaining procedure was
187 performed with the following combinations: CD3/CD8/CD45/CD4,
188 CD45RA/CD45RO/CD8/CD3, CD45RA/CD45RO/CD4/CD3 and
189 CD3/CD16⁺56/CD45/CD19. The antibody in each position was marked with a
190 fluorochrome as follows: FITC/PE/PerCP-Cy5.5/APC. After lysis of the red blood cells,
191 the lymphocytes were analyzed by flow cytometry (FACScan Plus Dual Laser, Becton
192 Dickinson Sunnyvale, CA). The percentage of each lymphocyte subset was obtained,
193 and absolute cell counts were calculated from the total lymphocyte numbers. The
194 CD4⁺/CD8⁺ ratio was also calculated.

195

196 **2.4 Statistical analyses**

197

198 Prior to statistical analyses, all data were examined for normal distributions with the
199 Kolmogov-Smirnov test, as well as for homogeneity of variances with the Levene Test.
200 When necessary, the normal distribution was obtained after logarithmic transformation
201 of the variable. The differences between the whole group of ED patients (ED) and the
202 control group, as well as the differences between each one of the different subtypes and
203 the control group were assessed by Student's t-test. Significant differences between ED
204 diagnostic subtypes were calculated using one-way analysis of variance
205 (ANOVA). When the analysis indicated a significant difference, the Tukey method was
206 used for a pair-wise comparison between the different diagnostic subtypes.

207

208 To assess the effect of the BMI Z-score on immuno-hematological variables, a
209 basic lineal regression model was used and corrected by age. In a second model, the
210 diagnostic subtype was also included as a potential influential factor. Differences were
211 considered statistically significant at $P < 0.05$. Statistical analysis was performed using
212 the IBM SPSS statistical software version 22.

213

214

215 **3. RESULTS**

216

217 The anthropometric measurements tested are summarized in Table 1. BMI and weight
218 were significantly lower in ED, ANR, ANP and FED-NEC than in the control group.

219 Among the different diagnostic groups, weight is significantly lower in ANR and ANP
220 compared to FED-NEC, and BMI is lower in ANR than in the other two groups.

221

222 Regarding white blood cells, lower leukocyte counts were found in ED girls
223 compared to healthy girls ($p=0.019$) (Table 2). Both the percentages and total
224 neutrophil, monocyte and basophil cell numbers were significantly decreased in the ED
225 group versus the control group. On the contrary, a significant increase was observed in
226 the lymphocyte percentage, while lymphocyte counts were similar to those in the
227 control group. Comparing the different diagnostic subtypes with the control group
228 separately, a decreasing trend in leukocyte numbers was found in ANR ($P=0.074$) and
229 ANP ($P=0.091$). The decrease in the monocyte and basophil percentages and counts was
230 observed in all of the diagnostic subtypes, while the increase in the lymphocyte
231 percentage was only significant in the ANR group ($P=0.007$). In addition, the neutrophil
232 percentage and counts were lower both in ANR and ANP than in the controls, however,
233 in ANP it did not reach statistical significance due to the small group size. The
234 eosinophil population showed a higher percentage in FED-NEC and ANP ($p=0.022$ and
235 $p=0.007$, respectively) versus controls, but no differences were found for the eosinophil
236 counts. No relevant differences among ED groups were observed in the different white
237 blood cell types, except for higher eosinophil percentage in ANP compared with ANR.

238

239 The assessment of the different lymphocyte subsets (Table 3) showed only a few
240 significant differences among diagnostic groups, while important differences were
241 observed in relation to the control group. The whole group of ED patients showed
242 higher CD4+ and CD19+ lymphocyte percentages and lower CD8+ and NK percentages
243 compared to the controls. In relation to the naïve and memory subsets percentage, ED

244 patients showed significantly lower CD8RO+ and higher CD8RA+ percentages than the
245 controls. On the contrary, no significant differences in CD4RA+ and CD4RO+
246 percentages were found when compared with controls. When focusing on the different
247 diagnostic subtypes, the formerly described results are also observed in the ANR group.
248 Referring to ANP, the higher CD4+ lymphocyte percentage observed in relation to
249 controls is even higher than the one observed in the other two subtypes.

250

251 Regarding lymphocyte subset counts, it is remarkable that no differences in CD4+
252 and naïve and memory CD4+ subset counts were observed between the ED subjects and
253 controls. However, lower CD8+, NK and memory CD8+ counts were found with an
254 increase in CD19+ cell numbers in relation to the control group. By diagnostic subtypes,
255 CD8+ cell counts were lower only in the FED-NEC, and CD19+ were higher only in
256 ANR. The changes in CD4+ and CD8+ subsets in ED led to a significantly higher
257 CD4:CD8 ratio in the patients (and in all the different subtypes) than in the control
258 group. ANP and ANR showed higher naïve CD8+ percentage and significantly lower
259 memory CD8+ percentage and counts than controls. Oppositely, no differences were
260 found between these two groups and neither against the control group for naïve and
261 memory CD4+. On the contrary the FED-NEC group showed lower naïve CD4
262 percentage than controls and a trend towards lower naïve CD8 counts compared to the
263 controls and the other ED subtypes.

264

265 The results of the general lineal model assessing the effect of age, BMI Z-score
266 and diagnostic subtype on leukocyte profile and lymphocyte subsets (Tables 4 and 5)
267 showed a BMI Z-score influence in lymphocyte counts and percentage, which is
268 diagnostic subtype independent. The BMI Z-score in the basic model showed a

269 significantly positive relationship with the CD3+CD4+CD45RO+ and
270 CD45+CD3(CD56+16)+ percentages and a negative relationship with CD3+, CD19+
271 counts, as well as with CD4+CD45RA+ percentage and counts. No influence of the
272 diagnostic subtype was found when this was included in the model.

273

274 **4. DISCUSSION**

275

276 The present study explored the alterations in white blood cells and in the
277 lymphocyte subset profile of AN patients of either the restrictive or binge-purging
278 subtype, as well as in a group of patients with FED-NEC, all in their first episode of the
279 disorder and with a short period of evolution. In agreement with our hypothesis,
280 lymphocyte cell variations were differentially influenced by body mass loss in AN
281 patients. Among all lymphocyte subsets analyzed, the associations with the BMI Z-
282 score were significant for the naïve CD4+ and the B lymphocyte numbers, which seems
283 to reflect an adaptive mechanism to preserve the adaptive immune response.

284 Our results are in agreement with all previous reports describing leucopenia with
285 relative lymphocytosis as the most frequent immune abnormality in AN [1, 8,], as well
286 as low neutrophil, monocyte and basophil counts in relation to the control group [27-
287 30]. In our study relative lymphocytosis was not found in the FED-NEC or ANP
288 groups.

289

290 The decrease in the percentage and absolute number of CD8+ T cells observed in
291 the patients, seem to be explained by the significant decrease in memory CD8+ T cells.
292 Similar findings for CD8+ cells have been previously described in AN patients by
293 several authors [1, 7, 8, 13]; and particularly Mustafa et al. [7] also reported a

294 diminished population of memory CD8+ cells. A decrease in the capacity of dendritic
295 cells to expand memory T cell clones might explain this finding, according to the results
296 that have also been observed in starvation animal models [31]. In contrast with the
297 CD8+ decrease and as a main finding in the current study, an increase in CD4+
298 percentage was found in our patients, which could be considered as a successful attempt
299 to preserve CD4+ absolute numbers under restricted intakes and reduced leukocyte
300 numbers. Thus, CD4 + lymphocyte cell levels maintenance could be understood as a
301 fundamental issue within the adaptation process to low intakes, and also a key factor
302 explaining why patients do not suffer an increased infection risk as classical forms of
303 protein-energy malnutrition. The increased CD4+ percentage has been also described in
304 other studies with AN patients [7, 13, 32]. Similarly, the increased B cell counts in our
305 patients are consistent with the generally agreed concept that humoral immunity is well
306 preserved in these patients [2, 33]. This increase was only observed in the ANR group
307 and seems to be linked to the body mass loss as well as the relative lymphocytosis
308 adaptive mechanism, since both lymphocytes and B lymphocytes are negatively
309 associated with the BMI z-score. Similarly, the negative relationship found in our
310 patients between the BMI Z-score and CD4+CD45RA+ cells, both percentage and
311 counts, suggests that as the body weight is depleted, the production of lymphocytes is
312 prioritized over that of other immune cells and, in the case of T lymphocytes, the
313 priority is laid on naïve T helper cells. This might be an attempt to preserve the efficacy
314 of the adaptive immune response under the food deprivation status. It might also be
315 related with the finding of Omodei et al. [27] who observed that the PBMCs from AN
316 patients showed lower activity of its major energy-producing pathways than those from
317 the controls. It might be worth investigating whether the priority in lymphocyte
318 production aims to compensate for a decreased metabolic activity.

319

320 We further tested the occurrence of this adaptation mechanism in the most
321 undernourished girls by comparing those girls with $<-2SD$ Z-score BMI (n=13) values
322 with those girls that showed the less undernourished status (Z-score BMI $>-1SD$; n=12).
323 This analysis showed that the most undernourished girls had significantly higher
324 lymphocyte counts and CD4+CD45RA+ counts than the less undernourished girls
325 (2438±641 vs. 1928±498 and 527±286 vs. 338±168, respectively), and also a trends for
326 a higher percentage of CD4+CD45RA+ (P=0.065).

327

328 ANP and ANR showed similar adaptive mechanisms regarding lymphocyte
329 subsets in the context of reduced leukocytes. As in ANR, only NK cells and memory
330 cytotoxic T cells were decreased in ANP; however, the low CD3+CD8+CD45RO+
331 counts were more significant in ANP than in ANR. Likewise, Nagata et al. [13] found
332 significantly decreased CD8+ counts in 6 patients with ANP compared to controls and a
333 similar non-significant trend in 7 patients with restricting-type AN. The effect of
334 vomiting on lymphocyte subsets has also been analyzed, showing that vomiting as a
335 purging strategy is associated with a more deleterious effect on T cells [15]. The
336 acquisition of purging-compensatory habits might be working as a strain on the already
337 restrained body [33].

338

339 FED-NEC patients' NK cells were less significantly diminished than those of both
340 AN subtypes. Malnutrition severity as well as the time of evolution of the disease could
341 be important factors explaining the variability observed since FED-NEC are, in our
342 sample, patients with initial disorders that have relatively shorter periods of evolution
343 than the other groups, however, no conclusions can be derived from this small and

344 heterogeneous group. Similarly, the low number of patients with ANP compared to
345 ANR might be considered as another limitation in this study; however, this was a
346 convenience sample and reflects the disparity in both subtypes incidence at first
347 episode. Despite this, the results showing a priority in the production of naïve T cells
348 was common to both ED subtypes, and the question arises whether this mechanism
349 aimed to preserve the adaptive immune response is maintained in those patients with
350 longer duration of disease and unsuccessful treatments. Future works with follow-up
351 data from immune assessments performed in this study population will hopefully solve
352 this limitation and will add information on the usefulness of these immunological
353 parameters as biomarkers of disease evolution.

354

355 No influence of the BMI Z-score was observed on the NK cell subset in our study,
356 nor was it observed in eosinophil percentage. However, the eosinophil percentage
357 seemed to be influenced by the diagnostic subtype. ANP showed higher values than
358 ANR, but it is not clear if this can be explained exclusively by the prevalence of allergy
359 by groups, which was 33%, 18% and 17% in FED-NEC, ANP and ANR subtypes,
360 respectively. It is important to note the endocrine changes known to occur in patients
361 with AN [34, 35] because pituitary-adrenal-cell mediated immunity interrelationships
362 seem to be disrupted [36]. Furthermore, some issues that frequently co-exist with AN,
363 such as depression or stressful life events [37-40], are themselves known to adversely
364 impact on immune function, and it is difficult to separate their effects. The impact of
365 these processes, or others, derived from the physiological adjustment secondary to ED
366 is likely to confuse the measurement of immune abnormalities.

367

368 In conclusion, our study of patients suffering their first episode of AN or FED-
369 NEC showed that relative lymphocytosis results from an enhanced production of naïve
370 CD4+ T cells and B cells as body mass loss progresses. This seems to be an adaptation
371 mechanism to maintain lymphocyte numbers, and likely, the adaptive immune response.
372

373 **5. ACKNOWLEDGEMENTS**

374 The authors sincerely thank all families that volunteered to participate in this
375 study.
376

377 **Funding:** This work was supported by the Ministry of Health (FIS PI08/1832) and
378 Alicia Koplowitz Foundation (2009).

379

380 **CONFLICT OF INTEREST:** none.

381

382 **References**

383

384 [1] Marcos A, Varela P, Santacruz I, Muñoz-Velez A MG. Nutritional status and
385 immunocompetence in eating disorders. A comparative study. *Eur J Clin Nutr*
386 1993;787–793.

387 [2] Nova E, Marcos A. Immunocompetence to assess nutritional status in eating
388 disorders. *Expert Rev Clin Immunol* 2006;2:433–44. doi:10.1586/1744666X.2.3.433.

389 [3] Marcos A, Varela P, Toro O, López-Vidriero I, Nova E, Madruga D, et al.
390 Interactions between nutrition and immunity in anorexia nervosa: a 1-y follow-up study.
391 *Am J Clin Nutr* 1997;66:485S–490S.

392 [4] Nova E, Gómez-Martínez S, Morandé G, Marcos A. Cytokine production by
393 blood mononuclear cells from in-patients with anorexia nervosa. *Br J Nutr*
394 2002;88:183–8. doi:10.1079/BJNBJN2002608.

395 [5] Erhabor O, Adias TC. *Haematology made easy*. Annotated edition. AuthorHouse.
396 2013.

397 [6] Cason J, Ainley CC, Wolstencroft RA, Norton KR, Thompson RP. Cell-
398 mediated immunity in anorexia nervosa. *Clin Exp Immunol* 1986;64:370–5.

399 [7] Mustafa A, Ward A, Treasure J, Peakman M. T lymphocyte subpopulations in
400 anorexia nervosa and refeeding. *Clin Immunol Immunopathol* 1997;82:282–9.

401 [8] Fink S, Eckert E, Mitchell J, Crosby R, Pomeroy C. T-lymphocyte subsets in
402 patients with abnormal body weight: longitudinal studies in anorexia nervosa and
403 obesity. *Int J Eat Disord* 1996;20:295–305. doi:10.1002/(SICI)1098-
404 108X(199611)20:3<295::AID-EAT9>3.0.CO;2-J.

- 405 [9] Allende LM, Corell A, Manzanares J, Madruga D, Marcos A, Madroño A, et al.
406 Immunodeficiency associated with anorexia nervosa is secondary and improves after
407 refeeding. *Immunology* 1998;94:543–51.
- 408 [10] do Carmo I, Palma-Carlos ML, Melo A, Jorge Z, Macedo A, Nunes S, et al.
409 Characterization of leukocytes, lymphocytes and lymphocyte subsets in eating
410 disorders. *Allerg Immunol (Paris)* 1997;29:261–8.
- 411 [11] Nova E, Lopez-Vidriero I, Varela P, Toro O, Casas J, Marcos A. Indicators of
412 nutritional status in restricting-type anorexia nervosa patients: a 1-year follow-up study.
413 *Clin Nutr* 2004;23:1353–9. doi:10.1016/j.clnu.2004.05.004.
- 414 [12] Nova E, Varela P, López-Vidriero I, Toro O, Ceñal MJ, Casas J, et al. A one-
415 year follow-up study in anorexia nervosa. Dietary pattern and anthropometrical
416 evolution. *Eur J Clin Nutr* 2001;55:547–54. doi:10.1038/sj.ejcn.1601181.
- 417 [13] Nagata T, Tobitani W, Kiriike N, Iketani T, Yamagami S. Capacity to produce
418 cytokines during weight restoration in patients with anorexia nervosa. *Psychosom Med*
419 1999;61:371–7.
- 420 [14] American Psychiatric Association. *DSM V: Diagnostic and Statistical Manual of*
421 *Mental Disorders*. 5th edition. Washington, DC. American Psychiatric Association:
422 2013.
- 423 [15] Marcos A, Varela P, Toro O, Nova E, López-Vidriero I, Morandé G. Evaluation
424 of nutritional status by immunologic assessment in bulimia nervosa: influence of body
425 mass index and vomiting episodes. *Am J Clin Nutr* 1997;66:491S–497S.
- 426 [16] Castellini G, Lo Sauro C, Mannucci E, Ravaldi C, Rotella CM, Faravelli C, et al.
427 Diagnostic crossover and outcome predictors in eating disorders according to DSM-IV
428 and DSM-V proposed criteria: a 6-year follow-up study. *Psychosom Med* 2011;73:270–
429 9. doi:10.1097/PSY.0b013e31820a1838.

- 430 [17] De Filippo E, Marra M, Alfinito F, Di Guglielmo ML, Majorano P, Cerciello G,
431 et al. Hematological complications in anorexia nervosa. *Eur J Clin Nutr* 2016;70:1305–
432 8. doi:10.1038/ejcn.2016.115.
- 433 [18] Lawson EA, Eddy KT, Donoho D, Misra M, Miller KK, Meenaghan E, et al.
434 Appetite-regulating hormones cortisol and peptide YY are associated with disordered
435 eating psychopathology, independent of body mass index. *Eur J Endocrinol*
436 2011;164:253–61. doi:10.1530/EJE-10-0523.
- 437 [19] Villaseñor, A. Anorexia nervosa. Hospital care at home (HCH). An adolescents
438 parent training programme. *Interpsiquis* 2011. 12º Congreso Virtual de Psiquiatría y
439 Neurociencias. 1-feb 2011.
440 <http://www.psiquiatria.com/bibliopsiquis/handle/10401/2202>;
441 <http://hdl.handle.net/10401/2202>
- 442 [20] Graell, M. Hospital care programme for school children and adolescents with
443 eating disorders. *Interpsiquis* 2011. 12º Congreso Virtual de Psiquiatría y
444 Neurociencias. 1-feb2011 <http://www.psiquiatria.com/bibliopsiquis/handle/10401/2203>.
445 <http://hdl.handle.net/10401/2203>
- 446 [21] American Psychiatric Association. *DSM IV: Diagnostic and Statistical Manual*
447 *of Mental Disorders*. 4th edition. Washington, DC. American Psychiatric Association:
448 1994.
- 449 [22] Herpertz-Dahlmann B, van Elburg A, Castro-Fornieles J, Schmidt U. ESCAP
450 Expert Paper: New developments in the diagnosis and treatment of adolescent anorexia
451 nervosa-a European perspective. *Eur Child Adolesc Psychiatry* 2015;24:1153–67.
452 doi:10.1007/s00787-015-0748-7.

- 453 [23] Fairburn CG, Bohn K. Eating disorder NOS (EDNOS): an example of the
454 troublesome "not otherwise specified" (NOS) category in DSM-IV. *Behav Res Ther*
455 2005;43:691–701. doi:10.1016/j.brat.2004.06.011.
- 456 [24] Veiga OL, Gómez-Martínez S, Martínez-Gómez D, Villagra A, Calle ME,
457 Marcos A: Physical activity as a preventive measure against overweight, obesity,
458 infections, allergies and cardiovascular disease risk factors in adolescents: AFINOS
459 Study protocol. *BMC Public Health* 2009; 9: 475.
- 460 [25] Sobradillo B, Aguirre A, Aresti U, Bilbao A, Fernández Ramos C, Lizárraga A,
461 et al. *Curvas y tablas de Crecimiento y Desarrollo (Estudio Longitudinal y Transversal)*.
462 Bilbao: Fundación Faustino Orbegozo; 2004.
- 463 [26] Calder PC. Immunological parameters: what do they mean? *J Nutr*
464 2007;137:773S–80S.
- 465 [27] Omodei D, Pucino V, Labruna G, Procaccini C, Galgani M, Perna F, et al.
466 Immune-metabolic profiling of anorexic patients reveals an anti-oxidant and anti-
467 inflammatory phenotype. *Metabolism* 2015;64:396–405.
468 doi:10.1016/j.metabol.2014.10.025.
- 469 [28] Misra M, Aggarwal A, Miller KK, Almazan C, Worley M, Soyka LA, et al.
470 Effects of Anorexia Nervosa on Clinical, Hematologic, Biochemical, and Bone Density
471 Parameters in Community-Dwelling Adolescent Girls. *Pediatrics* 2004;114:1574–83.
472 doi:10.1542/peds.2004-0540.
- 473 [29] Hütter G, Ganepola S, Hofmann W-K. The hematology of anorexia nervosa. *Int*
474 *J Eat Disord* 2009;42:293–300. doi:10.1002/eat.20610.
- 475 [30] Cleary BS, Gaudiani JL, Mehler PS. Interpreting the Complete Blood Count in
476 Anorexia Nervosa. *Eat Disord* 2010;18:132–9. doi:10.1080/10640260903585540.

- 477 [31] Abe M, Akbar F, Matsuura B, Horiike N, Onji M. Defective antigen-presenting
478 capacity of murine dendritic cells during starvation. *Nutrition* 2003;19:265–9.
- 479 [32] Saito H, Nomura K, Hotta M, Takano K. Malnutrition induces dissociated
480 changes in lymphocyte count and subset proportion in patients with anorexia nervosa.
481 *Int J Eat Disord* 2007;40:575–9. doi:10.1002/eat.20417.
- 482 [33] Marcos A, Nova E, Montero A. Changes in the immune system are conditioned
483 by nutrition. *Eur J Clin Nutr* 2003;57:66–9. doi:10.1038/sj.ejcn.1601819.
- 484 [34] Galusca B, Prévost G, Germain N, Dubuc I, Ling Y, Anouar Y, et al.
485 Neuropeptide Y and α -MSH Circadian Levels in Two Populations with Low Body
486 Weight: Anorexia Nervosa and Constitutional Thinness. *PLoS One* 2015;10:e0122040.
487 doi:10.1371/journal.pone.0122040.
- 488 [35] Nova E., Marcos A. Immunity in Anorexia Nervosa. In: *Nutrition, Immunity &*
489 *Infection*. Chapter 9. Philip Calder and Anil Kulkarni, Editors. CRC Press/Taylor &
490 Francis Group 2017, in press.
- 491 [36] Chiappelli F, Gwirtsman HE, Lowy M, Gormley G, Nguyen LD, Nguyen L, et
492 al. Pituitary-adrenal-immune system in normal subjects and in patients with anorexia
493 nervosa: the number of circulating helper T lymphocytes (CD4) expressing the homing
494 receptor Leu8 is regulated in part by pituitary-adrenal products.
495 *Psychoneuroendocrinology* 1991;16:423–32.
- 496 [37] Blinder BJ, Cumella EJ, Sanathara VA. Psychiatric comorbidities of female
497 inpatients with eating disorders. *Psychosom Med* 2006;68:454–62.
498 doi:10.1097/01.psy.0000221254.77675.f5.
- 499 [38] Strober M, Johnson C. The need for complex ideas in anorexia nervosa: Why
500 biology, environment, and psyche all matter, why therapists make mistakes, and why

501 clinical benchmarks are needed for managing weight correction. *Int J Eat Disord*
502 2012;45:155–78. doi:10.1002/eat.22005.

503 [39] Brambilla F. Social stress in anorexia nervosa: a review of immuno-endocrine
504 relationships. *Physiol Behav* 2001;73:365–9.

505 [40] Lasselin J, Alvarez-Salas E, Grigoleit J-S. Well-being and immune response: a
506 multi-system perspective. *Curr Opin Pharmacol* 2016;29:34–41.
507 doi:10.1016/j.coph.2016.05.003.

508

Table 1. Anthropometric parameters in controls and patients with eating disorders.

	CONTROL	ED	FEDNEC	ANP	ANR	P value [#]
	n=90	n=66	n=9	n=11	n=46	
Age (years)	14.86±1.17	14.62±1.38	14.44±1.24	15.27±1.42	14.50±1.38	0.230
Weight (kg)	56.98±8.97	42.08±6.45***	49.92±5.65* ^a	43.92±3.80*** ^b	40.11±5.84*** ^b	0.000
Height (m)	1.63±0.06	1.61±0.07 ^o	1.61±0.05	1.63±0.04	1.61±0.08 ^o	0.850
BMI (kg/m ²)	21.29±2.99	16.05±1.84***	19.12±1.23* ^a	16.45±0.75*** ^b	15.36±1.45*** ^c	0.000
Duration of disease (months)		10.97±8.16	7.11±3.41	15.18±8.85	10.72±8.32	0.110

Values are expressed as means±SD

BMI, body mass index; ED: eating disorder patients; FED-NEC: Feeding or eating disorders not elsewhere classified; ANP: AN purging subtype; ANR: AN restricting subtype.

Asterisks indicate differences versus control; Student's t test. *P<0.05, **P<0.01, ***P<0.001, ^oP<0.1

#ANOVA among ED groups.

Different letters indicate significant differences between ED groups. Tukey test; $P < 0.05$.

Table 2. White blood cell counts and differential in adolescents with AN and FEDNEC.

	CONTROL	ED	FED-NEC	ANP	ANR	
	n=90	n=66	n=9	n=11	n=46	P value [#]
Leukocytes (cel./ μ L)	6612 \pm 1736	5962 \pm 1612*	5841 \pm 1590	5673 \pm 1602 ^o	6055 \pm 1643 ^o	0.78
Lymphocytes (%)	35.6 \pm 9.1	38.9 \pm 9.5*	35.5 \pm 12.6	36.7 \pm 11.1	40.0 \pm 8.3**	0.153
Lymphocytes (cel./ μ L)	2300 \pm 617	2260 \pm 636	1950 \pm 494	2049 \pm 771	2370 \pm 606	0.011
Neutrophils (%)	53.7 \pm 9.6	50.5 \pm 10.2*	54.4 \pm 14.2	49.4 \pm 12.8	50.1 \pm 8.6*	0.156
Neutrophils (cel./ μ L)	3624 \pm 1406	3094 \pm 1305*	3264 \pm 1740	2869 \pm 1484 ^o	3115 \pm 1186*	0.871
Monocytes (%)	7.0 \pm 1.5	4.4 \pm 1.5***	4.6 \pm 1.5*** ^{a, b}	5.3 \pm 2.7** ^a	4.1 \pm 1.0*** ^b	0.092
Monocytes (cel./ μ L)	461 \pm 151	259 \pm 100***	272 \pm 126***	281 \pm 88***	251 \pm 99***	0.424
Basophils (%)	1.4 \pm 0.5	0.9 \pm 0.4***	0.8 \pm 0.4**	1.0 \pm 0.5*	0.9 \pm 0.4***	0.466
Basophils (cel./ μ L)	94 \pm 41	53 \pm 27***	43 \pm 17***	55 \pm 31**	55 \pm 28***	0.297
Eosinophils (%)	2.2 \pm 1.1	2.7 \pm 2.1	3.4 \pm 2.1* ^{a, b}	3.6 \pm 2.2** ^a	2.4 \pm 2.1 ^b	0.039
Eosinophils (cel./ μ L)	150 \pm 84	159 \pm 115	188 \pm 100	196 \pm 111	144 \pm 118	0.358

Values are expressed as means \pm SD

ED: eating disorder patients; FED-NEC: feeding or eating disorders not elsewhere classified; ANP: AN purging subtype; ANR: AN restricting subtype.

Asterisks indicate differences versus control; Student's t test: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, ° $P < 0.1$

#ANOVA among ED groups adjusted by age.

Different letters indicate significant differences between ED groups. Tukey test; $P < 0.05$

Table 3. Lymphocyte subsets in adolescents with anorexia nervosa and FED-NEC.

		CONTROL	ED	FED-NEC	ANP	ANR	P value [#]
		n=90	n=66	n=9	n=11	n=46	
CD45+CD3+ Mature T lymphocytes	%	70.2±6.5	69.4±5.9	65.0±5.8* ^a	74.3±4.7* ^b	69.1±5.4 ^a	0.003
	cel./μL	1613±455	1567±464	1275±374*	1527±609	1634±427	0.023
CD45+CD4+ T-Helper lymphocytes	%	37.8±6.7	41.6±6.3***	40.4±4.5 ^a	46.6±4.8*** ^b	40.6±6.5* ^a	0.018
	cel./μL	872±287	933±305	792±245	960±392	955±291 ^o	0.182
CD45+CD8+ T-Cytotoxic lymphocytes	%	26.9±5.7	23.6±4.9***	23.2±5.7 ^o	25.2±4.7	23.4±4.8***	0.676
	cel./μL	619±218	530±184**	452±149*	508±188	551±189 ^o	0.137
CD45+CD3(CD56+16)+ NK cells	%	16.4±6.6	10.4±4.5***	14.6±6.0 ^a	9±5.6*** ^b	9.9±3.4*** ^b	0.022
	cel./μL	382±193	230±106***	279±134	172±108**	234±96***	0.141
CD45+CD19+ B-lymphocytes	%	10.9±2.8	12.7±4.4**	11.8±4.0	11.0±3.1	13.3±4.6**	0.168
	cel./μL	249±88	293±149*	232±114	236±165	319±147**	0.007
CD3+CD45RO+ Memory T-lymphocytes	%	49.6±9.9	42.9±11.5***	47.6±15.4	40.5±11.2**	42.6±10.6***	0.526
	cel./μL	788±249	656±220*	586±206*	609±248*	683±216*	0.138

		CONTROL	ED	FED-NEC	ANP	ANR	P value [#]
		n=90	n=66	n=9	n=11	n=46	
CD4+CD45RA+ Naïve T-helper lymph.	%	48.3±10.4	47.0±12.0	39.6±12.1*	46.3±13.3	48.6±11.4	0.152
	cel./μL	428±181	453±228	331±192	455±240	478±230	0.127
CD3+CD4+CD45RO+ Memory T-helper lymph.	%	26.4±5.0	26.3±7.6	28.8 ±8.7	29.0 ±8.2	25.1 ±7.1	0.116
	cel./μL	420±141	398±133	354±103	443±204	396±116	0.859
CD8+CD45RA+ Naïve T-cytotoxic lymph.	%	58.1±13.2	64.0±12.0**	57.1±18.6 ^a	72.2±8.8** ^b	63.7±11.5* ^{a,b}	0.117
	cel./μL	360±152	341±134	262±132 ^o	364±132	351±134	0.121
CD3+CD8+CD45RO+ Memory T-cytotoxic lymph.	%	14.5±5.7	11.0±5.0***	12.9±7.2	8.4±3.4**	11.3±4.7**	0.396
	cel./μL	234±118	169±91***	158±97 ^o	127±60***	182±94**	0.127
Ratio CD4+/CD8+		1.49±0.48	1.84±0.52***	1.85±0.55*	1.92±0.47**	1.82±0.54***	0.934

Values are expressed as means ±SD

ED: eating disorder patients; FED-NEC: feeding or eating disorders not elsewhere classified; ANP: AN purging subtype; ANR: AN restricting subtype.

Asterisks indicate differences versus control; Student's t test. *P≤0.05, **P≤0.01, ***P≤0.001, ^oP≤0.1

[#]ANOVA among ED groups adjusted by age.

Different letters indicate significant differences between ED groups. Tukey test; $P < 0.05$.

Table 4. Associations between BMI Z-score and white blood cells in ED patients.

	Basic model ^a				Basic model + diagnostic subtype ^b		
	BMI-Z score			R ²	BMI-Z score	Diagnostic subtype	R ²
	β	95% CI	P		P	P	
Leukocytes (cel./ μ L)	-0.042	(-0.863,0.626)	0.752	0.013	0.996	0.880	0.017
Lymphocytes (%)	-0.311	(-9.244,-1.067)	0.014	0.138	0.039	0.815	0.143
Lymphocytes (cel./ μ L)	-0.329	(-0.631,-0.102)	0.007	0.201	0.081	0.891	0.204
Neutrophils (%)	0.213	(-0.699,8.274)	0.097	0.098	0.121	0.544	0.116
Neutrophils (cel./ μ L)	0.090	(-0.399,0.809)	0.500	0.009	0.459	0.707	0.020
Monocytes (%)	0.291	(0.008,0.119)	0.026	0.081	0.048	0.079	0.155
Monocytes (cel./ μ L)	0.192	(-0.012,0.080)	0.143	0.054	0.161	0.519	0.074
Basophils (%)	-0.100	(-0.255,0.114)	0.448	0.027	0.461	0.505	0.049
Basophils (cel./ μ L)	-0.143	(-0.019,0.006)	0.273	0.05	0.694	0.737	0.060
Eosinophils (%)	0.190	(-0.034,0.218)	0.150	0.045	0.972	0.067	0.126
Eosinophils (cel./ μ L)	0.135	(-0.026,0.080)	0.307	0.023	0.809	0.403	0.051

^a Lineal regression adjusted by age.

^b General lineal model including diagnostic subtype as independent factor and Z-score and age as covariates.

β , Standardized regression coefficient; CI, confidence interval

Table 5. Associations between BMI Z-score and lymphocyte subsets in ED patients.

		Basic model				Basic model + diagnostic subtype ^b		
		BMI-Z score			R ²	BMI-Z	Diagnostic	R ²
		β	95% CI	P		score	subtype	
					P	P		
CD45+CD3+	%	-0.200	(-4.692,0.601)	0.127	0.054	0.532	0.005	0.205
Mature T lymphocytes	cel./μL	-0.353	(-482.222,-91.465)	0.005	0.182	0.077	0.884	0.185
CD45+CD4+	%	0.010	(-2.779,3.001)	0.939	0.048	0.894	0.033	0.151
T-Helper lymphocytes	cel./μL	-0.250	(-270.159,2.236)	0.054	0.092	0.189	0.702	0.102
CD45+CD8+	%	0.042	(-1.901,2.619)	0.752	0.011	0.504	0.607	0.028
T-Cytotoxic lymphocytes	cel./μL	-0.221	(-154.180,10.493)	0.086	0.096	0.369	0.928	0.098
CD45+CD3(CD56+16)+	%	0.316	(0.500,4.450)	0.015	0.097	0.420	0.053	0.142
NK cells	cel./μL	0.058	(-38.323,60.070)	0.660	0.014	0.753	0.103	0.085
CD45+CD19+	%	-0.118	(-2.873,1.068)	0.363	0.050	0.938	0.449	0.078
B-lymphocytes	cel./μL	-0.267	(-32.98,-7.325)	0.029	0.188	0.291	0.749	0.196
CD3+CD45RO+	%	0.228	(-0.758,9.775)	0.092	0.047	0.199	0.606	0.063
Memory T-lymphocytes	cel./μL	-0.147	(-155.503,43.536)	0.265	0.079	0.815	0.756	0.088

CD4+CD45RA+	%	-0.279	(-11.228,-0.515)	0.032	0.085	0.352	0.739	0.094
Naïve T-helper lymph.	cel./ μ L	-0.296	(-219.600,-18.221)	0.021	0.117	0.134	0.839	0.122
CD3+CD4+CD45RO+	%	0.283	(0.374,7.108)	0.030	0.115	0.130	0.697	0.126
Memory T-helper lymph.	cel./ μ L	-0.060	(-76.307,48,407)	0.656	0.004	0.564	0.572	0.021
CD8+CD45RA+	%	-0.114	(-8.461,3.390)	0.395	0.012	0.802	0.026	0.126
Naïve T-cytotoxic lymph.	cel./ μ L	-0.235	(-116.232,5.403)	0.073	0.076	0.427	0.443	0.101
CD3+CD8+CD45RO+	%	0.063	(-1.818,2.914)	0.645	0.006	0.621	0.153	0.066
Memory T-cytotoxic lymph.	cel./ μ L	-0.167	(-67.293,14.946)	0.208	0.075	0.419	0.442	0.100

^a Lineal regression adjusted by age.

^b General lineal model including diagnostic subtype as an independent factor and Z-score and age as covariates

β , Standardized regression coefficient; CI, confidence interval